Interferon-containing and interferon-free HCV therapy for HIV-infected patients

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 72-78

  Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

direct acting antivirals; hepatitis C virus interferon; human immunodeficiency virus; NS5A inhibitors; polymerase inhibitors; protease inhibitors

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; END STAGE LIVER DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; MIXED INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; COMPLICATION; DRUG COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; MORTALITY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84899619873     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371012     Document Type: Article

References (50)

1. van der Helm J., Geskus R., Sabin C., et al. CASCADE Collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology: 2013; 144 4 751 760, e2
2. Wandeler G., Gsponer T., Bregenzer A., et al. Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis: 2012; 55 10 1408 1416
3. Kirk G. D., Mehta S. H., Astemborski J., et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med: 2013; 158 9 658 666
4. Ly K. N., Xing J., Klevens R. M., Jiles R. B., Ward J. W., Holmberg S. D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med: 2012; 156 4 271 278
5. Kaplan J. E., Benson C., Holmes K. K., et al. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep: 2009; 58 (RR-4): 1 207; quiz CE1-4
6. Rockstroh J. K., Bhagani S., Benhamou Y., et al. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med: 2008; 9 2 82 88 (Pubitemid 351228130)
7. Torriani F. J., Rodriguez-Torres M., Rockstroh J. K., et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med: 2004; 351 5 438 450 (Pubitemid 38988593)
8. Chung R. T., Andersen J., Volberding P., et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med: 2004; 351 5 451 459 (Pubitemid 38988594)
9. Rodriguez-Torres M., Slim J., Bhatti L., et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials: 2012; 13 3 142 152
10. Limketkai B. N., Mehta S. H., Sutcliffe C. G., et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA: 2012; 308 4 370 378
11. Berenguer J., Alvarez-Pellicer J., Martín P. M., et al. GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology: 2009; 50 2 407 413
12. Mehta S. H., Genberg B. L., Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health: 2008; 33 3 126 133
13. Mehta S. H., Lucas G. M., Mirel L. B., et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS: 2006; 20 18 2361 2369 (Pubitemid 44789539)
14. Butt A. A., Justice A. C., Skanderson M., Good C., Kwoh C. K. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther: 2006; 24 4 585 591 (Pubitemid 44127839)
15. Kramer J. R., Kanwal F., Richardson P., Mei M., El-Serag H. B. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol: 2012; 56 2 320 325
16. Naggie S., Sulkowski M. S. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology: 2012; 142 6 1324 1334, e3
17. Cacoub P., Rosenthal E., Halfon P., Sene D., Perronne C., Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat: 2006; 13 10 678 682 (Pubitemid 44401196)
18. McGowan C. E., Monis A., Bacon B. R., et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology: 2013; 57 4 1325 1332
19. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
20. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
21. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
22. Jacobson I. M., Gordon S. C., Kowdley K. V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 2013; 368 20 1867 1877
23. Sulkowski M. S., Gardiner D. F., Rodriguez-Torres M., et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med: 2014; 370 3 211 221
24. Kowdley K. V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med: 2014; 370 3 222 232
25. Kane M., Yadav S. S., Bitzegeio J., et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature: 2013; 502 7472 563 566
26. Lane H. C., Davey V., Kovacs J. A., et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med: 1990; 112 11 805 811 (Pubitemid 20182780)
27. Asmuth D. M., Murphy R. L., Rosenkranz S. L., et al. AIDS Clinical Trials Group A5192 Team. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis: 2010; 201 11 1686 1696
28. Sulkowski M. S., Cooper C., Hunyady B., et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol: 2011; 8 4 212 223
29. Sherman K. E., Shire N. J., Rouster S. D., et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology: 2005; 128 2 313 327 (Pubitemid 40431085)
30. Eyster M. E., Fried M. W., Di Bisceglie A. M., Goedert J. J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood: 1994; 84 4 1020 1023 (Pubitemid 24245863)
31. Daar E. S., Lynn H., Donfield S., et al. Hemophilia Growth and Development Study. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis: 2001; 183 4 589 595 (Pubitemid 32147515)
32. Thomas D. L., Shih J. W., Alter H. J., et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis: 1996; 174 4 690 695 (Pubitemid 26325882)
33. Balagopal A., et al. Antiretroviral therapy, Interferon Sensitivity, and Virologic Set Point in HIV-Hepatitis C Virus Co-infected Patients. Hepatology: 2014;; In press
34. Hadziyannis S. J., Sette H. Jr, Morgan T. R., et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med: 2004; 140 5 346 355
35. Sulkowski M., Pol S., Mallolas J., et al. P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis: 2013; 13 7 597 605
36. Sulkowski M. S., Sherman K. E., Dieterich D. T., et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med: 2013; 159 2 86 96
37. Dieterich D. T., et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 andHIV-1: primary analysis of the C212 study. 14th European AIDs Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS9/5.
38. Jacobson I., et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Paper presented at: 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, Netherlands
39. Manns M., et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-2, a phase III trial. Paper presented at: 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, Netherlands
40. Rodriguez-Torres M., et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV infected patients who are HIV coinfected with HIV. Paper presented at: ID Week 2013; October 2-6, 2013; San Francisco, CA
41. Sulkowski M. S., et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Paper presented at: The 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC
42. Osinusi A., Meissner E. G., Lee Y. J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA: 2013; 310 8 804 811
43. van Heeswijk R. P., Beumont M., Kauffman R. S., Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther: 2013; 18 4 553 560
44. Seden K., Back D., Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother: 2009; 64 1 5 8
45. Wilby K. J., Greanya E. D., Ford J. A., Yoshida E. M., Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol: 2012; 11 2 179 185
46. Deeks E. D. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs: 2013
47. Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol: 2013; 59 4 885 888
48. Schmidt W. N., Nelson D. R., Pawlotsky J. M., Sherman K. E., Thomas D. L., Chung R. T. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol: 2013
49. Thomas D. L., Leoutsakas D., Zabransky T., Kumar M. S. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc: 2011; 14 22
50. von Schoen-Angerer T., Cohn J., Swan T., Piot P. UNITAID can address HCV/HIV co-infection. Lancet: 2013; 381 9867 628